Alaunos Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3.0K | $0 | $0 | $2.0K | $5.0K | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $388.0K | $427.0K | $362.0K | $469.0K | $185.0K | $347.0K | $-87.0K | $143.0K |
| SG&A Expense | $564.0K | $585.0K | $548.0K | $718.0K | $854.0K | $747.0K | $846.0K | $1.0M |
| Operating Income | $-952.0K | $-1.0M | $-907.0K | $-1.2M | $-1.0M | $-1.1M | $-754.0K | $-1.2M |
| Operating Margin | — | — | -30,233.3% | — | — | -54,600.0% | -15,080.0% | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-952.0K | $-1.0M | $-893.0K | $-1.2M | $-1.1M | $-1.1M | $-741.0K | $-1.1M |
| Net Margin | — | — | -29,766.7% | — | — | -53,650.0% | -14,820.0% | — |
| EPS (Basic) | $-0.41 | $-0.59 | $-0.35 | $-0.55 | $-0.63 | $-0.67 | $-0.46 | $-0.70 |
| EPS (Diluted) | $-0.41 | $-0.59 | $-0.35 | $-0.55 | $-0.63 | $-0.67 | $-0.46 | $-0.70 |
| Shares Outstanding (Basic) | 2.4M | 1.9M | 1.9M | 2.2M | 1.7M | 1.6M | 1.6M | 1.6M |
| Shares Outstanding (Diluted) | 2.4M | 1.9M | 1.9M | 2.2M | 1.7M | 1.6M | 1.6M | 1.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |